Clinical Trials Browser

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumor

Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Lymphatic Metastasis

Neoplasm Metastasis

Gastric Cancer Peritoneal Metastases

Esophageal Neoplasms

Extensive Stage Lung Small Cell Cancer

Digestive System Neoplasms

Colonic Neoplasms

Esophageal Squamous Cell Carcinoma

Colorectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Gastric Cancer Stage

Carcinoma, Non-Small-Cell Lung

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Lymphoma, Follicular

Esophageal Neoplasms

Esophageal Neoplasms

Small Cell Lung Carcinoma

Esophageal Neoplasms, Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Stomach Neoplasms

Nasopharyngeal Carcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma

Hodgkin Disease, Recurrence

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung

Rectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Hypersensitivity, Triple Negative Breast Neoplasms

Left-sided Colorectal Cancer Complicating Acute Obstruction

Rectal Neoplasms

Stomach Neoplasms

Small Cell Lung Carcinoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Neoplasms, Endometrial Neoplasms

Carcinoma, Hepatocellular

Stomach Neoplasms

Hodgkin Disease

Glioblastoma

Uterine Cervical Neoplasms

Clinical Trials

TRIUNITE06

FMT-LUNG

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

ATARI-PDAC

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

MRD2START

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL

Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma

The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma

Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

OSCC

SPRING

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.

NeoSCLC-001

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma

Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

RATiFY

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer